Group 1: Investor Relations Activity Overview - The investor relations activity took place on May 26, 2025, at the company's conference room in Lianyungang, Jiangsu Province [4] - Attendees included representatives from Huaxia Fund and Xinda Securities, along with the company's chairman, general manager, and other key personnel [4] Group 2: Company Operations and R&D - The company conducted a site visit for the research units to observe the production and R&D facilities, including the formulation workshop and raw material drug workshop [5] - The management provided a comprehensive overview of the company's operational status and product development [5] Group 3: Key Questions and Responses - **Question 1**: Information on the innovative drug DYX116 - DYX116 is a first-class new drug developed in collaboration with WuXi AppTec, currently in Phase I clinical trials, expected to complete by the end of 2025 [6] - **Question 2**: Information on the innovative drug DYX216 - DYX216 is also a first-class new drug for treatment of resistant hypertension, with preliminary candidates identified [6] - **Question 3**: R&D plans for 2025 - The company plans to invest approximately CNY 163 million in R&D for 2025, with CNY 85 million allocated for innovative drugs and CNY 78 million for generic drugs [7] Group 4: R&D Focus and Goals - The R&D strategy will focus on chronic disease treatments characterized by metabolic disorders, including diabetes, hypertension, hyperlipidemia, and hyperuricemia [7] - For generic drugs, the company aims to initiate 10 projects, submit 7 formulation varieties and 3 raw material varieties to CDE, and strive for approvals of 6 formulation varieties and 2 raw material varieties [7] - The company will continue to advance projects like DYX116 and DYX216, integrating resources to accelerate the R&D process [7]